Two diagnostics and data firms reported strong preliminary fourth-quarter results driven by testing volume growth. Tempus disclosed preliminary Q4 revenue of about $367 million, an 83% year‑over‑year increase, and projected full‑year 2025 revenue around $1.27 billion; the firm attributed gains to oncology and hereditary testing and expanding data licensing contracts. Tempus also announced more than $1.1 billion in contract value from over 70 customers. Guardant Health reported preliminary Q4 revenue of roughly $280 million, a 39% increase driven by oncology and screening test volumes; the company expects full‑year 2025 revenue near $981 million. Both companies said testing growth and data products are the main commercial drivers as precision oncology adoption and population screening programs expand.